PD-1

[Cancer Research] The authors demonstrated that inhibition of fibroblast growth factor receptor 3 (FGFR3) in FGFR3-activated bladder cancer elevated PD-L1 protein levels by affecting its ubiquitination, thereby inhibiting the anti-tumor activity of CD8+ T cells.

[Science Advances] Scientists explored a critical role for programmed cell death 1 (PD-1) in brain tumor–initiating cells and uncovered a nonimmune resistance mechanism of patients with glioblastoma to PD-1– or programmed cell death ligand 1 (PD-L1)–blocking therapies.

[Advanced Science] Among various cell sources, FGL1/PD-L1 small extracellular vesicles (sEVs) derived from MSCs not only enriched FGL1/PD-L1 expression but also maintained the immunomodulatory properties of unmodified MSC sEVs.

[Cancer Gene Therapy] In the MC38 tumor model, combined administration of plasmids encoding IL-12 and an anti-PD-1 antibody induced significant anti-tumor responses, yet similar to the monotherapies.

[Journal of Translational Medicine] Researchers created a CAR-T that united in one product the two modalities: a CRISPR interference- circuit prevents programmed cell death protein 1 expression upon antigen-encounter.

[Cancer Research] Researchers demonstrated that the transcription factor SOX10 hindered immunogenicity of melanoma cells through the IRF4-IRF1 axis. Genetic and pharmacological approaches revealed that SOX10 repressed IRF1 transcription via direct induction of a negative regulator, IRF4.